Health & Biotech Dr Boreham’s Crucible: Can Lumos (ASX:LDX) light up the US with FDA approval? July 19, 2021 Lumos (ASX:LDX) listed on July 1 after a $63 million fund raising to further develop point-of-care diagnostics tools and aim… Wellnex Life rounds out first week after relisting on a high note July 16, 2021 Special Report: Wellnex Life has ended its first week after relisting on the ASX on a high, gaining roughly 37.5%… Incannex secures complete supply chain solution for its anti-inflammatory multi-use drug July 16, 2021 Special Report: Incannex has engaged Procaps to develop and manufacture its IHL-675A soft-gel capsules in preparation for clinical trials. ScoPo’s Powerplays: ASX biotech IPOs show ‘money is out there’; Virtus to benefit from rise in IVF July 16, 2021 Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains… Creso Pharma welcomes Senate Democrats’ bid to legalise cannabis July 16, 2021 Special Report: Creso Pharma (ASX:CPH) is applauding breakthrough legislation by Democratic leaders in the US Senate to legalise marijuana at… Weed Week: The CanCoin, cannabis tourism, and record medicinal product sales in Australia July 16, 2021 Technicorum Holdings announced The CanCoin – a cannabis token designed to solve market friction and monetisation in the European cannabis… These two ASX brain health stocks, boosted by FDA’s approval of Adulhelm, are kicking off clinical trials July 15, 2021 Brain health stocks are continuing to ride the wave of interest in the sector and two -Actinogen Medical (ASX:ACW) and… Creso Pharma completes acquisition of Canada-based Halucenex, set to enter the US$100 billion psychedelic market July 15, 2021 Special Report: The completion of Creso Pharma’s acquisition of Halucenex is set to unlock a number of lucrative opportunities, including… Wellnex Life gets set for launch as it rejoins the ASX boards with strong revenue growth July 15, 2021 Special Report: Following its successful BSA acquisition, the company is set for rapid revenue expansion in FY22. MGC Pharma set to commence Phase III clinical trial on CimetrA to treat COVID-19 patients July 13, 2021 European-based biopharma company MGC Pharma (ASX:MXC) has officially commenced the Phase III clinical trial to evaluate the efficacy and safety… Next» « Previous